Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Other Non Operating Income (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Other Non Operating Income for 6 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 36.04% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.3 million, a 24.46% decrease, with the full-year FY2025 number at $26.3 million, down 24.46% from a year prior.
  • Other Non Operating Income was $5.7 million for Q4 2025 at Relay Therapeutics, down from $6.2 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $9.0 million in Q1 2024 to a low of $157000.0 in Q3 2021.
  • A 5-year average of $5.1 million and a median of $6.4 million in 2025 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: tumbled 85.94% in 2021, then skyrocketed 1903.0% in 2022.
  • Relay Therapeutics' Other Non Operating Income stood at $267000.0 in 2021, then surged by 1903.0% to $5.3 million in 2022, then surged by 62.7% to $8.7 million in 2023, then grew by 3.15% to $9.0 million in 2024, then crashed by 36.04% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Other Non Operating Income are $5.7 million (Q4 2025), $6.2 million (Q3 2025), and $6.5 million (Q2 2025).